How glucagon-like peptide 1 receptor activators affect immune cells and autoimmune or inflammatory diseases

GLP-1 receptor agonists may have immune-regulating roles relevant to autoimmune and autoinflammatory diseases beyond diabetes and obesity treatment.

This review summarizes in vitro studies, preclinical models, and clinical observations on GLP-1R signaling in immune cells and diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis, asthma, multiple sclerosis, Sjögren's syndrome, and lupus.

The abstract describes therapeutic potential rather than definitive disease-specific efficacy, with evidence spanning mixed experimental and clinical observation types.